Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Last trade$3.72
Day change+$0.02 (+0.54%)
Day range$3.59 – $3.77
Volume833,362
Market cap$103M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$103.06M
Price / earnings
—
Price / book
1.93×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.78×
Profitability
Earnings per share
-$1.26
Return on assets
-48.9%
Return on equity
-66.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.81×
Quick ratio
3.81×
Cash ratio
2.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.85M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UNCY, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$7.35M
$6.83M
$4.97M
$4.38M
$5.21M
$5.82M
$3.97M
$3.21M
Research and development
$2.79M
$1.61M
$2.25M
$2.96M
$1.75M
$2.17M
$5.29M
$3.05M
Total operating expenses
$10.14M
$8.44M
$7.22M
$7.34M
$6.96M
$7.99M
$9.26M
$6.25M
Operating income
-$10.14M
-$8.44M
-$7.22M
-$7.34M
-$6.96M
-$7.99M
-$9.26M
-$6.25M
Interest expense
$0
$0
-$27K
-$15K
-$13K
-$15K
-$20K
-$15K
Income before taxes
-$1.72M
-$12.82M
-$14.67M
-$6.01M
-$6.45M
$570K
-$21.53M
-$4.1M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.72M
-$12.82M
-$14.67M
-$6.01M
-$6.45M
$570K
-$21.53M
-$4.1M
Net income attributable to common shareholders
-$1.72M
-$12.82M
-$14.67M
-$6.01M
-$6.45M
$570K
-$21.53M
-$4.1M
EBITDA
-$10.13M
-$8.43M
-$7.21M
-$7.33M
-$6.96M
-$7.98M
-$9.25M
-$6.25M
Basic earnings per share
-$0.06
-$0.54
-$0.68
-$0.33
-$0.52
$0.04
-$2.03
-$0.46
Diluted earnings per share
-$0.06
-$0.54
-$0.71
-$0.33
-$0.52
-$0.50
-$4.30
-$0.46
Recent news
Company coverage with links to the original publishers.
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly inspect or audit the vendor's facility, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate product. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case.
A class action lawsuit has been filed against Unicycive Therapeutics for allegedly making false and misleading statements regarding its third-party manufacturing vendor. The company allegedly failed to inspect the vendor's facility or audit compliance with manufacturing practices, creating undisclosed risks of FDA delays for oxylanthanum carbonate approval. Investors who purchased shares between December 29, 2025 and June 29, 2026 have until November 2, 2026 to apply as lead plaintiff.
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for believing deficiencies were remedied, creating material risk of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 2, 2026.
Rosen Law Firm issued deadline notices for securities class action lawsuits against Unicycive Therapeutics (UNCY), York Space Systems (YSS), and Papa John's International (PZZA). The UNCY lawsuit alleges the company made false statements about manufacturing compliance and FDA approval prospects for its oxylanthanum carbonate drug. Investors have until specified deadlines in late October and early November 2026 to join the class actions.
A class action lawsuit has been filed against Unicycive Therapeutics for alleged securities fraud. The complaint alleges that the company made false statements about its manufacturing vendor's FDA compliance and failed to disclose material risks regarding regulatory approval delays for oxylanthanum carbonate. Investors who purchased shares between December 29, 2025 and June 29, 2026 may be eligible to join the lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.